The NMIC-413 panel demonstrated exceptional reliability (Kappa> 0.9) for susceptibility testing of MEM, IPM, FEP, and SCF, supporting its clinical utility in guiding therapeutic decisions for severe infections. This evidence concerns the gene KITLG and infection.